A Personal Note.

By Bob Shapiro

Many of you know that I am living through Prostate Cancer. The treatments seem to be focused on using a couple of weeks here, or a couple of weeks there in an effort to add several months down the road.

I’ve had a good life- not that I’m rushing to say good-bye at 73 – and it’s been interesting to see how my priorities have been brought more clearly into focus.

I’ve been very happy sharing my ideas these last 5 years (whether I’ve written them or someone else) on my Blog and on Facebook. If you’ve found them worth your time enough to read some of them, well thank you.

Continue reading

New Urine Test May Show Whether Prostate Cancer Needs Treatment

By HealthDay – Re-Blogged From NewsMax Health

A man who learns he has prostate cancer faces a difficult choice: whether to immediately treat the cancer despite potential side effects or wait and see if it’s a slow-growing tumor that never needs treatment.

Men may soon have help making that decision.

Researchers from the United Kingdom report that they’ve created a urine test that can predict the aggressiveness of a prostate cancer far sooner than standard methods.

The new test is called the prostate urine risk test, or PUR. The researchers said it spots men who are up to eight times less likely to need radical treatment within five years of diagnosis. PUR also offers clues about who might need treatment five years sooner than current tests.

Advance in Slowing Prostate Cancer Made in Clinical Trials

By Health Day – Re-Blogged From Newsmax Health

Cutting-edge prostate cancer drugs that help extend life in the toughest cases might also be useful in fighting less aggressive tumors, two new clinical trials suggest.

Two drugs that interfere with cancer’s ability to use testosterone for fuel, apalutamide (Erleada) and enzalutamide (Xtandi), are already approved for use against more advanced prostate tumors that do not respond to regular therapy.

But these trials show the drugs also can improve survival and slow progression in prostate cancers that do respond to regular therapy, which typically involves medication that halts production of testosterone.

Study Proves Drug Cuts Prostate Cancer Risk

By Health Day – Re-Blogged From Newsmax Helth

Finasteride, best known as the enlarged-prostate medicine Proscar, is a safe, effective way to reduce the risk of prostate cancer, according to long-term findings from the Prostate Cancer Prevention Trial (PCPT).

The trial was funded by the U.S. National Cancer Institute and enrolled nearly 19,000 men between 1993 and 1997. Initially it found that finasteride — a hormone-blocking drug — cut the risk of prostate cancer by 25 percent. Those results were published in 2003.

The newly released long-term data show that the reduction of prostate cancer risk has continued and that fewer than 100 men in the trial died from prostate cancer in more than two decades of follow-up, according to a research team led by Dr. Ian Thompson.